Omics studies: their use in diagnosis and reclassification of SLE and other systemic autoimmune diseases.
Omics studies of systemic autoimmune diseases (SADs) in general, and SLE in particular, have delivered isolated information from transcriptome, epigenome, genome, cytokine and metabolome analyses. Such analyses have resulted in the identification of disease susceptibility genes and the description of IFN expression signatures, allowing extensive insight into the mechanisms of disease and the development of new therapies. Access to such technologies allows the recognition of patterns of disease at a pathway level, thereby, to reclassify SLE and other SADs and to develop new therapeutics from a personalized perspective. The use of omic information allows the discovery of correlative patterns involving drugs not currently suspected to be of value in SADs. In this review, we summarize the omics findings for SLE and propose ways of using the data for the identification of new biomarkers, finding new drugs and reclassifying patients not only with SLE, but also with other SADs.
Parque Tecnológico de la Salud, Medical Genomics, Centre Pfizer, University of Granada, Andalusian Regional Government for Genomics and Oncological Research, Granada, Spain.
Maria
M
Teruel
Experimental Medicine and Diagnostics, UCB, Slough, UK.
Chris
C
Chamberlain
Parque Tecnológico de la Salud, Medical Genomics, Centre Pfizer, University of Granada, Andalusian Regional Government for Genomics and Oncological Research, Granada, Spain.|Chronic Inflammatory Diseases Unit, Institute for Environmental Medicine, Karolinska Institutet, Solna, Sweden.
Marta E
ME
Alarcón-Riquelme
D001327:Autoimmune Diseases / Q000145:classification / Q000175:diagnosis / Q000235:genetics* / Q000276:immunology; D016207:Cytokines / Q000276:immunology; D055808:Drug Discovery; D057890:Epigenomics; D020869:Gene Expression Profiling; D020022:Genetic Predisposition to Disease; D023281:Genomics; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology; D055432:Metabolomics; D035683:MicroRNAs / Q000235:genetics
D016207:Cytokines; D035683:MicroRNAs
bioinformatics; drug repurposing; epigenomics; genomics; metabolomics; microRNAs; systematic autoimmunity; systematic lupus erythematosus; tnterferon signature; transcriptonomics